• Skip to main navigation
  • Skip to main content
  • Skip to Footer
  • English
    • Français
  • Canada
    • Novartis Site Directory
Novartis logo : a global healthcare company
  • Our Work
    • Our Process
    • Clinical Trials
    • Clinical Pipeline
    • Product Portfolio
  • About Us
    • Who We Are
    • Our Business
    • Corporate Responsibility
    • Contact Us
    • AODA Compliant
    • Grants and Donations
    • AMA Compliant
    • Biome Canada, Montreal
  • Our Products
    • Pharmaceuticals
    • Health Care Professional
    • For Consumers
  • News
    • Media Releases
    • Media Contacts
    • Stories
    • FAQ
    • COVID-19 commitments
  • Careers
    • Careers Search
    • Working at Novartis
    • Employee Benefits
    • Student Programs
Search

News Archive

The content below is specific to Novartis Canada. To see all Novartis content, please visit the Novartis Global site.

Advanced SearchBasic Search
2022

October

Media Release / Oct 14, 2022

Gene therapy Luxturna® now reimbursed in Quebec for people with previously untreatable inherited vision loss¹

Read More

September

Media Release / Sep 21, 2022

Novartis and the pan-Canadian Pharmaceutical Alliance (pCPA) conclude negotiations for Luxturna®, a gene therapy for previously untreatable inherited vision loss¹

Read More
Media Release / Sep 07, 2022

Health Canada approves PLUVICTO™ as first targeted radioligand therapy for progressive PSMA positive metastatic castration-resistant prostate cancer

Read More

August

Media Release / Aug 31, 2022

Scemblix™, a first-in-class CML treatment with new mechanism of action approved in Canada

Read More

June

Media Release / Jun 09, 2022

Novartis Pro Portal reimagines knowledge exchange in patient care, with seamless collaboration between the pharmaceutical industry and physicians

Read More
Media Release / Jun 09, 2022

Health Canada approves PrTabrecta®: Targeted cancer therapy for locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) exon 14 skipping alterations

Read More

April

Media Release / Apr 25, 2022

Ontario and Quebec become the first provinces to list Kesimpta® (ofatumumab) for the treatment of adults with relapsing remitting multiple sclerosis (RRMS)

Read More
2021

December

Media Release / Dec 17, 2021

Beovu® (brolucizumab injection) now publicly reimbursed in Ontario and New Brunswick for the treatment of neovascular (wet) age-related macular degeneration

Read More

October

Media Release / Oct 27, 2021

Novartis launches Not Another Minute to educate Canadians and take action to bend the curve of cardiovascular disease (CVD)

Read More
Media Release / Oct 19, 2021

Novartis applauds Quebec, the first province to list Zolgensma® for the treatment of pediatric patients with spinal muscular atrophy (SMA)

Read More
Search Results Navigation
  • Current page 1 of 3
  • Page 2 of 3
  • Page 3 of 3
  • Next page next ›
  • Last page last »
    • TwitterTweet
    • FacebookShare
    • Share
      • Twitter
      • Facebook
      • LinkedIn
      • Email

You are here

  1. Home ›
  2. News

Novartis Canada

  • Our Work
  • Notre travail
  • About Us
  • À propos de Novartis
  • Our Products
  • Nos Produits
  • News
  • Actualité
  • Careers
  • Carrière
  • Contact Us
  • Sites
  • Locations
  • Biome Canada, Montreal
  • Biome Canada, Montreal

Subscribe to Novartis

  • Twitter
  • Linkedin
  • Novartis Site Directory
© 2023 Novartis Pharmaceuticals Canada inc.
  • Terms of Use
  • Privacy Policy
  • Cookie Settings

This site is intended for an audience in Canada.